All In Biotech

NDA 012342 · Advanz Pharma

Parnate

Tranylcypromine Sulfate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 4, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1961

Feb 21, 1961

Approved uses

3

Original approval plus efficacy supplements

Registered trials

32

3 Phase 3, 1 recruiting

FAERS reports

804

501 serious, 40 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING:SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . Tranylcypromine sulfate tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)]. Hypertensive Crisis with Significant Tyramine Use Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with tranylcypromine sulfate tablets or after tranylcypromine sulfate tablets discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals...

What it is approved for

From the label in effect Jul 25, 2025.

Tranylcypromine sulfate tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4), Warnings and Precautions (5) , and Drug Interactions (7)]. Tranylcypromine sulfate tablets are a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants ( 1 ) Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions ( 1 , 4 , 5 , 7 )

Mechanism: The mechanism of action of tranylcypromine sulfate tablets as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PARNATE · TRANYLCYPROMINE SULFATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tranylcypromine" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective95
  • depression91
  • drug interaction80
  • headache72
  • contraindicated product administered68
  • nausea63
  • insomnia61
  • hypertensive crisis60
  • anxiety51
  • dizziness50
  • hypertension50
  • suicidal ideation46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200545
200653
200750
200859
200938
201039
201151
201227
201313
201412
201538
201644
201725
201829
201955
202030
202115
202221
202330
202440
202528
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Parnate (Tranylcypromine Sulfate)

2024 spending

$476K

Beneficiaries

36

231 claims

Per beneficiary

$13,229

$9.23 per unit

View as table
YearSpending
2020$667,545
2021$641,622
2022$606,886
2023$508,230
2024$476,241

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 99 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.